PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB "Super-Stimulation".
CAR generations
CAR-T
PSMA
cancer immunotherapy
prostate cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
05
2021
accepted:
07
09
2021
entrez:
18
10
2021
pubmed:
19
10
2021
medline:
19
10
2021
Statut:
epublish
Résumé
Prostate cancer (PCa) is the second leading cause of malignancy-related mortality in males in the Western world. Although treatment like prostatectomy and radiotherapy for localized cancer have good results, similar positive outcomes are not achieved in metastatic PCa. Consequently, these aggressive and metastatic forms of PCa urgently need new methods of treatment. We already described an efficient and specific second-generation (2G) Chimeric Antigen Receptor (CAR) against Prostate Specific Membrane Antigen (PSMA), a glycoprotein overexpressed in prostate cancer and also present on neovasculature of several tumor entities. In an attempt to improve efficacy and
Identifiants
pubmed: 34660275
doi: 10.3389/fonc.2021.708073
pmc: PMC8511814
doi:
Types de publication
Journal Article
Langues
eng
Pagination
708073Informations de copyright
Copyright © 2021 Zuccolotto, Penna, Fracasso, Carpanese, Montagner, Dalla Santa and Rosato.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Ther. 2009 Aug;17(8):1453-64
pubmed: 19384291
Blood. 2015 Jun 25;125(26):4017-23
pubmed: 25999455
Cancer Res. 2005 Feb 1;65(3):727-31
pubmed: 15705868
J Immunother Cancer. 2017 Mar 21;5:28
pubmed: 28331617
Nat Med. 2015 May;21(5):524-9
pubmed: 25849134
Blood. 2013 Feb 14;121(7):1165-74
pubmed: 23243285
Sci Transl Med. 2015 Sep 2;7(303):303ra139
pubmed: 26333935
Cell Rep. 2017 Oct 3;21(1):17-26
pubmed: 28978471
Hum Gene Ther. 2010 Jan;21(1):75-86
pubmed: 19719389
Cancer Immunol Res. 2015 Apr;3(4):368-79
pubmed: 25576337
Clin Adv Hematol Oncol. 2016 Oct;14(10):802-808
pubmed: 27930631
Mol Ther Oncolytics. 2020 Jun 23;18:202-214
pubmed: 32728609
Nat Med. 2015 Jun;21(6):581-90
pubmed: 25939063
Cancer Res. 2006 Nov 15;66(22):10995-1004
pubmed: 17108138
Clin Cancer Res. 2016 Jan 1;22(1):9-15
pubmed: 26728408
Blood. 2002 Mar 15;99(6):2009-16
pubmed: 11877273
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
Mol Ther. 2010 Feb;18(2):413-20
pubmed: 19773745
Immunotherapy. 2017 Aug;9(9):723-733
pubmed: 28771104
Mol Ther. 2013 Dec;21(12):2268-77
pubmed: 23985696
J Immunol. 2004 Dec 15;173(12):7125-30
pubmed: 15585832
Clin Cancer Res. 2015 Jul 1;21(13):2952-62
pubmed: 25691731
Curr Gene Ther. 2014 Feb;14(1):35-43
pubmed: 24365143
PLoS One. 2014 Oct 03;9(10):e109427
pubmed: 25279468
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5250-5
pubmed: 17875752
Eur J Cancer. 2013 Jun;49(9):2223-32
pubmed: 23433847
Hum Gene Ther. 2014 Dec;25(12):1003-12
pubmed: 24694017
Clin Cancer Res. 2019 Jul 1;25(13):4014-4025
pubmed: 30979735
Mol Ther Oncolytics. 2016 Apr 13;3:16006
pubmed: 27162934
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
Cancer Immunol Res. 2015 Feb;3(2):125-35
pubmed: 25212991
Nat Rev Drug Discov. 2015 Jul;14(7):499-509
pubmed: 26129802
Int J Cancer. 2011 Dec 15;129(12):2935-44
pubmed: 22030616
J Immunol. 1999 Mar 1;162(5):2858-66
pubmed: 10072534
Cancer Cell. 2015 Oct 12;28(4):415-428
pubmed: 26461090
JCI Insight. 2018 Jan 11;3(1):
pubmed: 29321369
Curr Mol Med. 2013 Aug;13(7):1079-88
pubmed: 23116267